Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA furlough threat

Executive Summary

FDAers and other HHS employees have been told to show up for work on Oct. 9 although the threat of furloughs has been revived by the House of Representative's 254 to 179 vote against the budget summit agreement on Oct. 5. On the same day, the government's stopgap omnibus spending bill expired and President Bush said he would not sign another temporary funding bill unless a budget resolution is passed. HHS made preparations to furlough FDAers for about seven days a month in case the Gramm-Rudman law goes into effect, but the agency said it would not do so during the first two weeks of October.

You may also be interested in...



Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU

Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.

Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US

Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.

Demand For Supplements Helps Bayer Outpace Global Market In 2020

Enjoying a 5% sales rise, Bayer Consumer Health grew faster than the global market last year, with the company keen to repeat the performance in 2021.

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel